PRF1 and neoplasm: Tregs regulate anti-tumor immune responses through multiple mechanisms, including the production of adenosine through co-expression of CD39/CD73, granzyme B, perforin, or Fas/FasL pathways, and the development of tolerogenic DCs, leading to the formation of a regulatory T cell subset in the TME [92,93].